Redeye Growth Day takes place on June 2 in Stockholm and will be a combination of a digital platform and live presentations. Lipum is "In Focus" at 11:20, link to the event.
Lipum will also participate in the annual European Congress of Rheumatology EULAR 2022, Copenhagen, Denmark, June 1-4, 2022. At the congress, Lipum's CSO Susanne Lindquist will present the poster "A Novel Target for Treatment of Inflammatory Joint Diseases".
Lipum also presents at BioStock Life Science Summit Spring on 8-9 June 2022 (digital) and Aktiespararnas småbolagsdag on 15 June in Stockholm.
For further information, please contact:
Einar Pontén, CEO
Mobile: +46 70 578 34 95
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: firstname.lastname@example.org, phone: +46 8 503 000 50.